{
    "Trade/Device Name(s)": [
        "Lyme B. burgdorferi (IgG) MarStripe Test",
        "Lyme B. burgdorferi (IgG) Immunoblot"
    ],
    "Submitter Information": "Immco Diagnostics, Inc. a Trinity Biotech Company",
    "510(k) Number": "K163095",
    "Predicate Device Reference 510(k) Number(s)": [
        "K950829"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR"
    ],
    "Summary Letter Date": "September 10, 2016",
    "Summary Letter Received Date": "November 4, 2016",
    "Submission Date": "January 4, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema pallidum treponemal test reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology",
        "serology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Borrelia burgdorferi proteins"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunoblot"
    ],
    "Methodologies": [
        "Qualitative detection of IgG antibodies by immunoblot"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Lyme B. burgdorferi (IgG) MarStripe immunoblot kit for qualitative detection of IgG antibodies to B. burgdorferi in serum and plasma.",
    "Indications for Use Summary": "For in vitro qualitative detection of human IgG antibody to individual proteins of Borrelia burgdorferi in serum or plasma from samples previously found positive or equivocal by EIA or IFA, to provide supportive evidence of infection.",
    "fda_folder": "Microbiology"
}